Health Care • Biotechnology: Pharmaceutical Preparations
$2.37 ▼ -0.13
(-5.20%)
MKT CAP: $3.1M • VOL: 7.4K
52W L $2 52W H $105
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
JUNS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $21.8K | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | $17.6K | — | — |
| Gross Margin % | 80.6% | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$8.9M | -$3.1M | -$3.9M |
| Operating Margin % | -80.0% | — | — |
| Net Income (GAAP) | -$8.6M | -$2.4M | -$4.8M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$5.4M | -$3.9M | -$481.0K |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$5.4M | -$3.9M | -$481.0K |
| FCF Margin % | -80.0% | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$1.8M | $4.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JUNS.